Dr. Matthew J. Wieduwilt
Claim this profileUniversity of California San Diego
Affiliated Hospitals
University Of California, San Diego
University Of Oklahoma Health Sciences Center
Clinical Trials Matthew J. Wieduwilt is currently running
Acalabrutinib Maintenance
for Large B-cell Lymphoma
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Recruiting
1 award
Phase 1 & 2
24 criteria
SNDX-5613 + Chemotherapy
for Acute Myeloid Leukemia
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding SNDX-5613 to the standard chemotherapy treatment may be able to shrink or stabilize the cancer for longer than the standard chemotherapy treatment alone.
Recruiting
1 award
Phase 1
More about Matthew J. Wieduwilt
Clinical Trial Related
3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Matthew J. Wieduwilt has experience with
- Liposome-encapsulated Daunorubicin-Cytarabine
- Azacitidine
- Venetoclax
- Enasidenib Mesylate
- Gemtuzumab Ozogamicin
- Decitabine
Breakdown of trials Matthew J. Wieduwilt has run
Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew J. Wieduwilt specialize in?
Matthew J. Wieduwilt focuses on Acute Myeloid Leukemia and Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved IDH positive patients, or patients who are undergoing treatment.
Is Matthew J. Wieduwilt currently recruiting for clinical trials?
Yes, Matthew J. Wieduwilt is currently recruiting for 4 clinical trials in San Diego California. If you're interested in participating, you should apply.
Are there any treatments that Matthew J. Wieduwilt has studied deeply?
Yes, Matthew J. Wieduwilt has studied treatments such as Liposome-encapsulated Daunorubicin-Cytarabine, Azacitidine, Venetoclax.
What is the best way to schedule an appointment with Matthew J. Wieduwilt?
Apply for one of the trials that Matthew J. Wieduwilt is conducting.
What is the office address of Matthew J. Wieduwilt?
The office of Matthew J. Wieduwilt is located at: University of California San Diego, San Diego, California 92103 United States. This is the address for their practice at the University of California San Diego.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.